Intarcia Therapeutics

Intarcia
Pharma

Intarcia’s diabetes delivery system faces FDA refusal to approve

After issuing two complete response letters and denying three dispute resolution requests, the FDA now plans to refuse to approve Intarcia’s filing.
Nick Paul Taylor Sep 7, 2021 10:50am